Statins to Prevent Cancer-Associated Blood Clots in Cancer Patients
Official title: (2/2) Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT): DCC
Funded at Brigham and Women's Hospital · NIH-11387857 · Data updated 2026-11-12
A large clinical trial will test whether taking rosuvastatin daily for a year helps prevent dangerous blood clots in people with newly diagnosed or relapsed cancer who aren’t already getting anticoagulants.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2025 |
| Project end | July 31, 2032 |
| Funding year | 2026 |
| Award (this year) | $739,320 |
| NIH project number | 5U24HL176626-02 |
| Project ID | NIH-11387857 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with newly diagnosed or recently relapsed cancer at moderate-to-high risk for VTE who are not planned for anticoagulation and are not currently on statins.
✕Less likely to help
Patients without recently diagnosed or relapsed cancer, or those already planned for anticoagulation, may not benefit.
What this research studies
In this trial, eligible cancer patients at high risk of clots will be randomly assigned to rosuvastatin 20 mg daily or placebo for 12 months. The study aims to see if rosuvastatin can reduce venous thromboembolism without increasing bleeding, building on evidence from prior trials. A computable-phenotype tool will help researchers efficiently identify and enroll eligible participants. The trial will enroll up to 4,000 participants across multiple centers, starting from 2025.
Why it matters
Potential benefit: If successful, rosuvastatin could provide a safer, non-anticoagulant option to lower clot risk in cancer patients.
How similar studies have gone: Previous large trials (JUPITER, HOPE-3) showed a reduction in VTE with rosuvastatin, supporting exploration in cancer patients.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Glynn, Robert J — Brigham and Women's Hospital
- Study coordinator: Glynn, Robert J
Related research
Other NIH-funded projects on the same topics.
-
Statins to Prevent Cancer-Associated Blood Clots in Cancer Patients
A large study will test whether taking rosuvastatin every day for a year can lower the chance of dangerous blood clots in people with cancer, without raising the risk of bleeding.
-
Optimal use of blood thinners for venous clots in people with cirrhosis
This grant hopes to figure out the safest and most effective way to use oral anticoagulants for adults with cirrhosis who develop venous clots.
-
PET/CT imaging to detect chemotherapy-related vascular harm in young cancer patients
A non-invasive PET/CT scan method using standard care imaging is being tested to identify which pediatric and young adult cancer patients are at higher risk of blood clots from chemotherapy.
-
BCOR's role in blood clot risk and liver genetics
A Johns Hopkins-led study is exploring how a human gene, BCOR, may control liver-produced clotting factors to influence venous blood clots.
-
Personalized risk-prediction for hospital-acquired blood clots in adults
A real-time risk model helps doctors identify adults in the hospital who are at higher risk of developing blood clots so they can prevent them safely.
-
Genomic and Proteomic Markers for Recurrent Venous Thromboembolism
Researchers are studying genetic and protein clues to predict who will have another blood clot after an initial VTE event, so doctors can tailor safer, more effective care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.